Targeting egfr-sglt1 interactions for cancer therapy

摘要

PROBLEM TO BE SOLVED: To provide methods and compositions capable of properly treating cancer cells being resistant to EGFR tyrosine kinase inhibitors.SOLUTION: A compound according to the invention can inactivate the binding interaction between epidermal growth factor receptor (EGFR) and sodium/glucose co-transporter 1 (SGLT1). In one embodiment, the compound is a peptide derived from an interaction domain of EGFR. In anther embodiment, the compound is administered to a patient to treat cancer.SELECTED DRAWING: None